 CONSHOHOCKEN, Pa., Nov. 23, 2021 GLOBE NEWSWIRE -- Madrigal Pharmaceuticals, Inc. NASDAQ: MDGL, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis NASH, announced today its management team will participate in two upcoming virtual investor conferences: 